

Genetics Report

Patient details:


Sample details:

Clinical Summary: CML on imatinib for 18 months. For *BCR-ABL1* monitoring by RT-qPCR.

BCR-ABL1 quantitative PCR (RT-qPCR) monitoring report (transcript type = e13a2/e14a2)

Treatment response	<i>BCR-ABL1:ABL1</i> % ratio on IS	MR level	Date next sample due
Failure	1.6905	MR ¹	As clinically required

Please note that this result could signify a resistance to treatment that may be due to an acquired mutation in the *ABL1* kinase domain (AKD) of the *BCR-ABL1* fusion gene and therefore AKD mutation testing should be considered. Please notify the laboratory if AKD testing is required on the current sample.



Reported by:

Authorised by:

Laboratory Number (Sample Type)	Date received	Copies of <i>BCR-ABL1</i>	Copies of <i>ABL1</i>	<i>BCR-ABL1:ABL1</i> ratio (IS)	<i>BCR-ABL1:ABL1</i> ratio on IS (%)	Sensitivity of detection (1/ <i>ABL1</i>)	Molecular Response (MR)
	17/02/2016	660,000	784,000	1.178	117.84	0.000001	
	16/05/2016	25,000	55,000	0.634	64.43	0.000018	#NA
	04/08/2016	3,500	94,000	0.052	5.24	0.000011	MR ¹
	28/11/2016	8,300	137,000	0.085	8.51	0.000007	MR ¹
	12/02/2017	3,200	140,000	0.032	3.17	0.000007	MR ¹
	13/04/2017	4,000	120,000	0.047	4.67	0.000008	MR ¹
	25/07/2017	1,200	106,000	0.016	1.59	0.000009	MR ¹
	06/09/2017	1,200	99,000	0.017	1.69	0.000010	MR ¹